MedTrace Logo

The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

NCT05642910 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2022-12-08

No results posted yet for this study

Summary

This is a randomized controlled clinical study on the clinical efficacy of Azvudine and Paxlovid antivirus therapy in COVID-19 patients with high-risk. The objective is to examine the effect of high-risk on the time for COVID-19 patients to achieve 2 continuously negative SARS-CoV-2 nucleic acid test result, and the RT-PCR negative conversion rates in day 7. Patients who meet inclusion criteria will be randomized into the Azvudine group (treatment group) and Paxlovid group (control group).

Conditions

Interventions

DRUG

Azvudine

Patients received Azvudine orally, for 7 consecutive days (7 doses in total)

DRUG

Paxlovid group

Patients received Paxlovid orally for 5 consecutive days (10 doses in total).

Sponsors & Collaborators

  • Hohhot First Hospital, Hohhot, Inner Mongolia, China

    collaborator UNKNOWN

  • Southeast University, China

    lead OTHER

Principal Investigators

  • Songqiao Liu, MD. PhD. · Southeast university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2023-01-31
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05642910 on ClinicalTrials.gov